NCT03556280 · ACTIVE NOT RECRUITING
Multi-Center Study of Sensory Stimulation to Improve Brain Function
This trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma. Researchers are measuring whether it is safe, tolerable, and effective in people with mild to moderate cognitive impairment. This is a Phase NA randomized controlled trial, meaning it is a device study being evaluated for real-world benefit but not yet proven or approved.
You may qualify if
- >= 55 Years old
- MMSE 14-26
- Prodromal Alzheimer's Disease (AD), AD or Mild Cognitive Impairment (MCI) due to AD
- Participation of a caregiver
You're excluded if
- Profound hearing or visual impairment
- Seizure Disorder
- Use of memantine (Namenda or Namzaric)
- Implantable devices (non-MR compatible)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2021-08-24